Cannabidiol Shows Promise as Alternative Therapy for Canine Pyoderma

Strategic Insights -

Research conducted at Kasetsart University in Bangkok, Thailand, has highlighted the potential of cannabidiol (CBD) as a topical therapy for canine pyoderma, a common dermatological condition caused by methicillin-resistant Staphylococcus pseudintermedius (MRSP) and related strains. The study compared the in vitro antibacterial activity of Piper betel leaf extract nanoemulsion (BLN) and CBD formulations against canine Staphylococcus isolates. The results showed that BL and BLN demonstrated potent anti-staphylococcal activity, with median minimum inhibitory concentrations (MICs) of 0.16 g/L and 0.31 g/L, respectively. Ethanolytic and water-soluble CBD formulations exhibited the strongest activity, with median MICs of 0.003 g/L and 0.004 g/L, respectively. The study concluded that the novel BLN and soluble CBD formulations have significant potential as topical antiseptic alternatives to chlorhexidine, emphasizing the need for further in vivo studies to assess safety, efficacy, and formulation optimization.

Key Takeaways:

  • The study demonstrated the in vitro antibacterial activity of Piper betel extract nanoemulsion (BLN) and cannabidiol (CBD) formulations against canine Staphylococcus isolates.
  • BL and BLN exhibited potent anti-staphylococcal activity, with median MICs of 0.16 g/L and 0.31 g/L, respectively.
  • Ethanolytic and water-soluble CBD formulations displayed the strongest activity, with median MICs of 0.003 g/L and 0.004 g/L, respectively.
  • The study highlighted the potential of novel BLN and soluble CBD formulations as topical antiseptic alternatives to chlorhexidine for canine pyoderma management.
  • Further in vivo studies are required to assess safety, efficacy, and formulation optimization of these novel therapies.
  • The research was supported by the Agricultural Research Development Agency, with Kasetsart University researchers Wongsakorn Wongwatcharamongkhon, Pareeya Udomkusonsri, Natthasit Tansakul, Udomlak Sukatta, Suporn Thongyuan, Watsapol Suntoranan, and Chantima Pruksakorn contributing to the study.

Statistics:

  • 15 Staphylococcus isolates (five MRSP, five methicillin-susceptible S. pseudintermedius, and five MRSS) were tested against the in vitro antibacterial activity of BLN and CBD formulations.
  • 0.003 g/L and 0.004 g/L were the median MICs for ethanolytic and water-soluble CBD formulations, respectively.
  • 0.16 g/L and 0.31 g/L were the median MICs for BL and BLN, respectively.
  • 40.86% and 26.44% were the concentrations of eugenol and hydroxychavicol, respectively, as predominant antibacterial compounds revealed by gas chromatography-mass spectrometry (GC-MS).
  • The study highlighted the potential of BLN and soluble CBD formulations as topical antiseptic alternatives to chlorhexidine for canine pyoderma management.

Sources:

  • (1) NewsRx. Kasetsart University Researchers Highlight Recent Research in Cannabidiol (In vitro antibacterial activity of Piper betel extract nanoemulsion and cannabidiol formulations against methicillin-resistant Staphylococcus isolates from canine ...). Life Science Weekly. November 4, 2025; p 2136.
  • (2) In vitro antibacterial activity of Piper betel extract nanoemulsion and cannabidiol formulations against methicillin-resistant Staphylococcus isolates from canine pyoderma. Veterinary World, 2025,18(10):3017-3028. (Veterinary World - http://www.veterinaryworld.org).